Considering the clinical need for reliable determination of IDH mutational status and the emerging use of mutant IDH as a therapeutic target, such models have the potential not only to meaningfully complement pathological evaluation of the tumor but even to precede it and therefore support individualized surgical strategies. The gene discussed is IDH2; the disease is neoplasm.